Friday, 4 April 2025
Innovations in Lung Cancer Treatment: Insights from CheckMate 9LA and CheckMate 816 | Amicus
14:00-14:30
| Time | Presentations |
| 14:00—14:15 | CheckMate 816: The role of Nivolumab and Chemotherapy in the Neoadjuvant Treatment of NSCLC Prof. Dr. Bojan Zaric Institute for Pulmonary Diseases of Vojvodina |
| 14:15—14:30 | CheckMate 9LA: Combining Nivolumab and Ipilimumab and limited Chemotherapy in Advanced Lung Cancer Dr. Jelena Spasic Institute for Oncology and Radiology Serbia |
Friday, 4 April 2025
Navigating the advanced lung cancer treatment landscape: addressing hard-to-treat patients | AztraZeneca
15:55-16:55
Moderator: Prof. Dr. Bojan Zarić
| Time | Presentations |
| 15:55-16:00 | Welcome and introductions Prof. Dr. Bojan Zarić (Moderator) |
| 16:00-16:20 | Overcoming limitations with first-line immunotherapy in mNSCLC Marko Jakopović / Izidor Kern / Tanya Zlatanova (Panel) |
| 16:20-16:40 | Metastatic EGFRm NSCLC: re-defining possibilities through emerging therapies Marko Jakopović / Izidor Kern / Tanya Zlatanova (Panel) |
| 16:40-16:50 | Improving outcomes for patients with SCLC – today and tomorrow Marko Jakopović / Izidor Kern / Tanya Zlatanova (Panel) |
| 16:50-16:55 | Q&A |
Friday, 4 April 2025
Key to better outcomes in the treatment of non-small cell lung cancer| MSD
17:55-18:25
| Time | Presentations |
| 17:55-18:25 | Prof.dr Bojan Zaric, Institute for Pulmonary Diseases of Vojvodina Dr Jelena Spasic, Institute for Oncology and Radiology of Serbia |
Saturday, 5 April 2025
ALK Positive Metastatic NSCLC; Recent Advances and Patient Outcome Optimisation | Pfizer Oncology
10:15-11:15
| Time | Presentation |
| 10:15 – 10:30 | Treatment Options for 1st Line ALK Positive mNSCLC: An Overview of Recent Clinical Data Prof Dr Marko Jakopović (University Hospital Centre Zagreb, Croatia) |
| 10:30 – 10:45 | Optimising Treatment Outcomes for ALK Positive mNSCLC Patients: When & How Dr Abed Agbarya (Bnei Zion Medical Center, Israel) |
| 10:45 – 11:00 | Optimal First-Line Therapy Selection for ALK Positive mNSCLC Prof Dr Thorsten Fuereder (University Hospital Vienna, Austria) |
| 11:00 – 11:15 | Panel Discussion All panelists |